ZYVERSA THERAPEUTICS, INC. Operating Cash Flow
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Operating Cash Flow of -$799.12 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$799.12K.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$413.69K.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.41M.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was -$1.52M.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$5.11M.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$7.52M.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$8.72M.
| Period end | Net Cash Provided by (Used in) Operating Activities 1 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 11 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | -$799.12K 10-Q · filed 2026-05-13 | -$1.21M derived: sum of 2 quarters · filed 2026-05-13 | -$2.62M derived: sum of 3 quarters · filed 2026-05-13 | -$4.14M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-12-31 | -$413.69K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.82M derived: sum of 2 quarters · filed 2026-03-31 | -$3.34M derived: sum of 3 quarters · filed 2026-03-31 | -$5.11M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$2.93M derived: sum of 2 quarters · filed 2025-11-19 | -$4.70M 10-Q · filed 2025-11-19 | -$5.92M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-06-30 | -$1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$3.29M 10-Q · filed 2025-08-13 | -$4.51M derived: sum of 3 quarters · filed 2026-05-13 | -$5.12M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-03-31 | -$1.77M 10-Q · filed 2026-05-13 | -$2.99M derived: sum of 2 quarters · filed 2026-05-13 | -$3.60M derived: sum of 3 quarters · filed 2026-05-13 | -$5.51M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.83M derived: sum of 2 quarters · filed 2026-03-31 | -$3.74M derived: sum of 3 quarters · filed 2026-03-31 | -$7.52M 10-K · filed 2026-03-31 | -$7.56M 10-K · filed 2025-03-27 | |||
| 2024-09-30 | -$614.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$2.53M derived: sum of 2 quarters · filed 2025-11-19 | -$6.30M 10-Q · filed 2025-11-19 | -$6.34M 10-Q · filed 2024-11-14 | -$9.09M derived: sum of 4 quarters · filed 2025-11-19 | |||
| 2024-06-30 | -$1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$5.69M 10-Q · filed 2025-08-13 | -$8.48M derived: sum of 3 quarters · filed 2025-08-13 | -$9.41M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$3.78M 10-Q · filed 2025-05-12 | -$6.56M derived: sum of 2 quarters · filed 2025-05-12 | -$7.50M derived: sum of 3 quarters · filed 2025-05-12 | -$7.91M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | -$2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$3.72M derived: sum of 2 quarters · filed 2025-03-27 | -$4.13M derived: sum of 3 quarters · filed 2025-03-27 | -$8.72M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | -$936.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.34M derived: sum of 2 quarters · filed 2024-11-14 | -$5.93M 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | -$407.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$5.00M 10-Q · filed 2024-08-09 | ||||||
| 2023-03-31 | -$4.59M 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | -$3.39M 10-K · filed 2024-03-25 | |||||||
| 2022-12-12 | -$1.49M 10-K · filed 2024-03-25 | |||||||
| 2022-09-30 | -$126.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$616.66K derived: sum of 2 quarters · filed 2022-11-14 | -$714.83K 10-Q · filed 2022-11-14 | -$1.14M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2022-06-30 | -$490.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$588.35K 10-Q · filed 2022-08-15 | -$1.02M derived: sum of 3 quarters · filed 2022-08-15 | -$969.11K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2022-03-31 | -$98.17K 10-Q · filed 2022-05-13 | -$526.74K derived: sum of 2 quarters · filed 2022-05-13 | -$478.92K derived: sum of 3 quarters · filed 2022-11-14 | -$527.00K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-12-31 | -$428.58K derived: 10-K 9 month − 10-Q 6 month · filed 2022-04-15 | -$380.76K derived: sum of 2 quarters · filed 2022-11-14 | -$428.83K 10-K · filed 2022-04-15 | |||||
| 2021-09-30 | $47.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | -$257.00 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$48.08K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |